Dual immune checkpoint inhibition in metastatic renal cell carcinoma: Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial. Editorial Article uri icon

Overview

publication date

  • January 7, 2021

Research

keywords

  • Carcinoma, Renal Cell
  • Kidney Neoplasms

Identity

PubMed Central ID

  • PMC7808104

Scopus Document Identifier

  • 85100697189

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-20-2063

PubMed ID

  • 33421736

Additional Document Info

volume

  • 6

issue

  • 1